Bangalore: Biocon Ltd on Tuesday said initial data from late-stage clinical trials on its experimental oral insulin drug for diabetes did not meet the desired results, but said it was committed to the global development of the drug.
In the final-stage trials being conducted in India, IN-105 did not meet its primary target of lowering HbA1c levels, or a haemoglobin count, in patients with type 2 diabetes.
The patients were poorly controlled on the drug when compared to a placebo, India’s top-listed biotechnology firm said in a statement on Tuesday.
The firm was further assessing the data from the trial, Biocon said, adding that the drug had met secondary targets on efficacy and safety.
The company plans to start looking for a global pharmaceutical partner to continue the development of the drug, Managing Director Kiran Mazumdar-Shaw said in a statement.
A total of 264 patients were enrolled at multiple centers across India in the double-blind placebo controlled trial on the drug.